In short
Metabolic syndrome is any three of five simple measurements. You can have it at a normal weight, and about 9 per cent of normal weight people do.
- Waist over 102 cm in men, 88 cm in women
- Triglycerides 150 mg/dL or above
- HDL under 40 mg/dL in men, under 50 in women
- Blood pressure 130/85 or above
- Fasting glucose 100 mg/dL or above
It roughly doubles cardiovascular risk and raises the risk of type 2 diabetes three to five fold. The honest caveat: treatment is the same as treating the components.
Condition Overview
What is metabolic syndrome?
A cluster of five risk factors that travel together. Any three of them makes the diagnosis, and abdominal obesity is not required, though it is usually central to the picture.
| Waist | 102 cm or more in men, 88 cm or more in women. Ethnic specific thresholds are lower in some populations |
| Triglycerides | 150 mg/dL or above, or on treatment for them |
| HDL cholesterol | Under 40 mg/dL in men, under 50 in women, or on treatment |
| Blood pressure | 130/85 or above, or on treatment |
| Fasting glucose | 100 mg/dL or above, or on treatment |
How common is it?
Common enough that most executive audiences contain a lot of it. In United States survey data from 2021 to 2023, 38.5 per cent of adults met the criteria.
Prevalence rises steeply with age: 18.5 per cent at 20 to 39, 37.8 per cent at 40 to 59, and 62.5 per cent from 60. Globally it rose from 9 to 25.7 per cent in men between 2000 and 2023.
Can you have it at a normal weight?
Yes, and this is the part most people get wrong. In survey data, metabolic syndrome was present in 9 per cent of normal weight people, 33 per cent of those with overweight and 62 per cent of those with obesity.
The Framingham finding is sharper still. Normal weight people with metabolic syndrome had raised risks of both diabetes and cardiovascular disease. People with obesity but without metabolic syndrome did not.
What does it predict?
- Cardiovascular disease: relative risks of 1.53 to 2.18 across three meta analyses
- All cause mortality: relative risks of 1.27 to 1.60
- Type 2 diabetes: relative risks of 3.53 to 5.17 in a meta analysis of 16 cohorts
- Chronic kidney disease: odds ratio of 2.6, rising with the number of components
The honest criticism
The label itself may add little. The Framingham risk score predicted coronary disease and stroke more accurately than the presence of metabolic syndrome in a 20 year study of 5128 men.
Its critical weakness is that treatment of the syndrome is no different from treatment of its components. The value is in noticing the cluster, not in the name. If one component is present, the others are worth looking for.
When to See a Doctor
- One of the five has already been flagged: waist, triglycerides, HDL, blood pressure or glucose
- Your waist has increased even though your weight has not changed much
- You have had a corporate check that reported numbers without connecting them
- There is type 2 diabetes in your family
- You have polycystic ovary syndrome, fatty liver or sleep apnoea, all of which travel with this cluster
- Fasting glucose of 126 mg/dL or above, or HbA1c of 6.5 per cent or more, which is diabetes rather than risk
- Blood pressure persistently very high, which needs treating rather than monitoring
- Chest discomfort or breathlessness on exertion
How Dr. Felix Assesses This
-
1
The five measurements
Blood pressure, waist circumference, fasting lipid profile and fasting glucose. That is the whole assessment. The Endocrine Society suggests repeating it every three years in anyone with at least one risk factor.
-
2
HbA1c alongside glucose
Formal definitions do not include it, but an HbA1c of 5.7 to 6.4 per cent is increasingly used to define impaired glucose regulation in this setting and is more practical than a fasting sample.
-
3
Looking for the conditions that travel with it
Fatty liver, sleep apnoea, kidney function and albuminuria, and in women polycystic ovary syndrome. These are common enough alongside the cluster to be worth asking about.
-
4
Cardiovascular risk calculated properly
The syndrome label is not a substitute for a calculated risk. A validated risk score predicts events better than the label does, and it is what decides whether medication is warranted.
Treatment Options
Executive Health Assessment
Why is blood pressure the most commonly mishandled measurement? Because a single clinic reading in a rushed appointment is exactly…
View Treatment
CEO Health Assessment
Who does the doctor work for? You. That is worth stating because it is not always the case in a…
View Treatment
Men’s Executive Check
Should you have a PSA test? That is deliberately framed as a question. Prostate screening is a discussion, and your…
View Treatment
Annual Executive Medical Review
Why is the second review more informative than the first? Because a single value is a point and two values…
View Treatment
Why Early Treatment Can Matter
Does reversing it help?
The evidence suggests yes. In a retrospective cohort, reversal of metabolic syndrome was associated with a reduced risk of a major cardiovascular event, rate ratio 0.85.
Among the five components, recovery from high blood pressure was most strongly associated with the reduction. That is a useful ordering when deciding where to start.
What actually reverses it?
Weight reduction and increased physical activity are the primary treatment, and lifestyle intervention roughly doubled the odds of resolving the syndrome compared with control in a network meta analysis of randomised trials.
Multicomponent programmes with individual goal setting and attention to adherence work better than advice alone.
Why does waist matter more than weight?
Because it tracks the fat distribution that drives insulin resistance. A large waist alone identifies up to 46 per cent of people who will develop metabolic syndrome within five years.
Weight gain matters too. In the Framingham cohort, gaining 2.25 kg or more over 16 years raised the risk of developing the syndrome by 21 to 45 per cent.
Is insulin resistance worth measuring?
Usually not directly. It is uncertain whether measuring it adds anything to the five simple traits, which are cheaper, standardised and already predictive.
Inflammatory markers such as CRP are associated with the syndrome, but their value in managing it is unknown, and they explained only a small part of the link to coronary mortality in one study.
Why Early Treatment Can Matter
Does reversing it help?
The evidence suggests yes. In a retrospective cohort, reversal of metabolic syndrome was associated with a reduced risk of a major cardiovascular event, rate ratio 0.85.
Among the five components, recovery from high blood pressure was most strongly associated with the reduction. That is a useful ordering when deciding where to start.
What actually reverses it?
Weight reduction and increased physical activity are the primary treatment, and lifestyle intervention roughly doubled the odds of resolving the syndrome compared with control in a network meta analysis of randomised trials.
Multicomponent programmes with individual goal setting and attention to adherence work better than advice alone.
Why does waist matter more than weight?
Because it tracks the fat distribution that drives insulin resistance. A large waist alone identifies up to 46 per cent of people who will develop metabolic syndrome within five years.
Weight gain matters too. In the Framingham cohort, gaining 2.25 kg or more over 16 years raised the risk of developing the syndrome by 21 to 45 per cent.
Is insulin resistance worth measuring?
Usually not directly. It is uncertain whether measuring it adds anything to the five simple traits, which are cheaper, standardised and already predictive.
Inflammatory markers such as CRP are associated with the syndrome, but their value in managing it is unknown, and they explained only a small part of the link to coronary mortality in one study.
Reversal is measurable
Lifestyle intervention roughly doubled the odds of resolving the syndrome, and reversal was associated with a 15 per cent lower rate of major cardiovascular events.
What it leads to
Three to five fold higher risk of type 2 diabetes, roughly double the cardiovascular risk, and higher rates of fatty liver, kidney disease and sleep apnoea.
Five numbers
Blood pressure, waist, triglycerides, HDL and fasting glucose. No specialist test required, and repeatable every three years.
Cost & Consultation Investment
The five measurements are ordinary and inexpensive, and the consultation and panel are quoted before anything is ordered. Insulin levels, inflammatory markers and specialist metabolic panels are generally not ordered, because it is uncertain whether they add anything to the five simple traits. Where a further test is genuinely indicated, such as liver imaging or a sleep study, it is discussed and quoted first.
Frequently Asked Questions
Yes. About 9 per cent of normal weight people meet the criteria, and in Framingham data normal weight people with metabolic syndrome had raised diabetes and cardiovascular risk while people with obesity but without it did not.
Blood pressure, on the available evidence. Among the components, recovery from hypertension was most strongly associated with a reduction in cardiovascular risk.
The clustering is real. Whether the label adds anything is debated, because treatment is identical to treating each component and a calculated risk score predicts events better. Its practical value is that finding one component should prompt looking for the others.
Usually not. It is uncertain whether measuring insulin resistance adds anything beyond the five simple measurements, which are cheaper and already predictive.
For this purpose, yes. A large waist alone identifies up to 46 per cent of people who will develop the syndrome within five years, and it captures the fat distribution that drives insulin resistance.
Every three years in anyone with at least one risk factor, according to Endocrine Society guidance, and at routine visits otherwise.
Fatty liver, obstructive sleep apnoea, kidney function and albuminuria, and in women polycystic ovary syndrome. All are more common alongside the cluster and all are treatable.
Evidence
Where this information comes from
Every figure on this page is taken from the sources below. All of them are free to read, so you can check them yourself.
- Obesity and overweight
- Obesity: identification, assessment and management
- Semaglutide for managing overweight and obesity
- Cardiovascular diseases
This page is general medical information and does not replace a personal consultation. Trial results are averages across large groups, not a prediction for any one person.